Medicare Enrolled

Dr. Rao Moravineni, MD

Hematology & Oncology · Griffin, GA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
747 SOUTH 8TH STREET, Griffin, GA 30224
7702281767
In practice since 2006 (19 years)
NPI: 1669584447 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Moravineni from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Moravineni? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Moravineni

Dr. Rao Moravineni is a hematology & oncology specialist in Griffin, GA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Moravineni performed 1,544 Medicare services across 748 unique beneficiaries.

Between the years covered by Open Payments, Dr. Moravineni received a total of $151,145 from 45 pharmaceutical and/or device companies across 341 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Moravineni is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 27% volume in GA $151,145 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,544
Medicare services
Top 27% in GA for hematology & oncology
748
Unique beneficiaries
$54
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~81 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
1,000 $45 $213
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
185 $69 $314
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
172 $61 $210
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
69 $59 $317
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
49 $102 $484
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
33 $101 $400
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
20 $24 $129
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
16 $109 $422
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$151,145
Total received (2018-2024)
Avg $21,592/year across 7 years
Top 4% in GA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
45
Companies
341
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$91,409 (60.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$56,393 (37.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,813 (1.9%)
Other
Charitable contributions, space rental, and other categories
$529 (0.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$18,004
2023
$29,217
2022
$23,887
2021
$29,231
2020
$12,771
2019
$16,981
2018
$21,054

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
EMD Serono, Inc.
$5,232
Daiichi Sankyo Inc.
$4,435
Pharmacosmos Therapeutics Inc.
$2,661
BTG International, Inc.
$1,500
Regeneron Healthcare Solutions, Inc.
$1,357
AstraZeneca Pharmaceuticals LP
$594
PFIZER INC.
$346
SOBI, INC
$276
GENZYME CORPORATION
$210
ABBVIE INC.
$170
Astellas Pharma US Inc
$157
Merck Sharp & Dohme LLC
$149
Lilly USA, LLC
$145
Janssen Biotech, Inc.
$114
Takeda Pharmaceuticals U.S.A., Inc.
$80
Novartis Pharmaceuticals Corporation
$72
Exelixis Inc.
$61
Celgene Corporation
$55
Karyopharm Therapeutics Inc.
$52
Gilead Sciences, Inc.
$47
Genentech USA, Inc.
$42
Coherus Biosciences Inc.
$40
Sumitomo Pharma America, Inc.
$34
ARRAY BIOPHARMA INC
$28
Eisai Inc.
$24
Incyte Corporation
$20
Mirati Therapeutics, Inc.
$18
Deciphera Pharmaceuticals Inc.
$18
Alexion Pharmaceuticals, Inc.
$18
Bayer Healthcare Pharmaceuticals Inc.
$17
Agios Pharmaceuticals, Inc.
$17
GlaxoSmithKline, LLC.
$14
Top 3 companies account for 68.5% of 2024 payments
All-time payments by company (2018-2024) ›
Lilly USA, LLC
$42,443
Daiichi Sankyo Inc.
$23,338
Incyte Corporation
$20,451
Regeneron Healthcare Solutions, Inc.
$20,135
GENZYME CORPORATION
$8,301
CTI BioPharma Corp.
$5,239
EMD Serono, Inc.
$5,232
PFIZER INC.
$4,858
GlaxoSmithKline, LLC.
$4,229
Pharmacosmos Therapeutics Inc.
$2,661
Janssen Biotech, Inc.
$1,728
Karyopharm Therapeutics Inc.
$1,602
Exelixis Inc.
$1,531
BTG International, Inc.
$1,500
E.R. Squibb & Sons, L.L.C.
$1,382
Blueprint Medicines Corporation
$1,182
Ipsen Biopharmaceuticals, Inc
$1,020
AstraZeneca Pharmaceuticals LP
$594
JAZZ PHARMACEUTICALS INC.
$515
Novartis Pharmaceuticals Corporation
$356
Celgene Corporation
$303
SOBI, INC
$302
NOVARTIS PHARMACEUTICALS CORPORATION
$299
Astellas Pharma US Inc
$284
Myriad Genetic Laboratories, Inc.
$181
Athenex Pharmaceutical Division, LLC
$175
Gilead Sciences, Inc.
$172
ABBVIE INC.
$170
Merck Sharp & Dohme LLC
$169
Stemline Therapeutics Inc.
$149
Takeda Pharmaceuticals U.S.A., Inc.
$124
Cardinal Health 110 LLC
$100
Genentech USA, Inc.
$70
Mirati Therapeutics, Inc.
$65
Seattle Genetics, Inc.
$49
Coherus Biosciences Inc.
$40
Sumitomo Pharma America, Inc.
$34
ARRAY BIOPHARMA INC
$28
Eisai Inc.
$24
Foundation Medicine, Inc.
$20
Deciphera Pharmaceuticals Inc.
$18
Alexion Pharmaceuticals, Inc.
$18
Amgen Inc.
$18
Bayer Healthcare Pharmaceuticals Inc.
$17
Agios Pharmaceuticals, Inc.
$17
Top 3 companies account for 57.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BOSULIF · BRAFTOVI · CABOMETYX · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELREXFIO · ELZONRIS · ENHERTU · EPKINLY · Enhertu · FRUZAQLA · Fabhalta · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LORBRENA · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · MONJUVI · MONOFERRIC · MYRISK · NINLARO · Nplate · Nubeqa · ONIVYDE · ORGOVYX · OXBRYTA · Orserdu · Padcev · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · SARCLISA · SYNAGIS · TAGRISSO · TECENTRIQ · TECVAYLI · TIVDAK · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · Vistogard · Vonjo · XPOVIO
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (60%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for hematology & oncology in GA.

Looking for a hematology & oncology specialist in Griffin?
Compare hematology & oncology specialists in the Griffin area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
27
Per 100K population
39.6
County median income
$60,217
Nearest hospital
WELLSTAR SPALDING MEDICAL CENTER
6.3 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Moravineni is a clinical cardiology specialist, with above-average Medicare volume (top 27% in GA), with speaking/promotional industry engagement in the top 4% of GA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Moravineni experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Moravineni performed 1,000 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Moravineni receive payments from pharmaceutical companies?
Yes. Dr. Moravineni received a total of $151,145 from 45 companies across 341 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Moravineni's costs compare to other hematology & oncology specialists in Griffin?
Dr. Moravineni's average Medicare payment per service is $54. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Moravineni) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →